VectorY develops an innovative gene therapy platform with a focus on the development of treatments for nerve and muscle diseases. The VectorY platform combines the therapeutic potential of antibodies and gene therapy. The lead products focus on ALS, a fatal disease in which motor nerve cells deteriorate.

The Mibiton funding will be used to set-up the pilot facility, which will produce gene therapy products on a pilot scale.